Search Results

Zymo Research, a leader in biotechnological advancement has launched a new nuclease called PureRec Duplex-Specific Nuclease that selectively digests double stranded DNA.

In a groundbreaking development, Zymo Research, a leader in biotechnology innovation, has revolutionized large-scale production of animal-free recombinant RNase A, a challenge that persisted for over half a century.

Zymo Research Corporation proudly announced its sponsorship of the upcoming “Microbes in Wastewater: Molecular Approaches in Pathogen and AMR Surveillance” symposium, scheduled for January 18th -19th, 2024, in Laguna Beach, California.

Zymo Research announced today that the U.S. Food and Drug Administration (FDA) has cleared its DNA/RNA Shield™ SafeCollect™ Saliva Collection Kit as a Class II medical device for microbial nucleic acid storage and stabilization.

Zymo Research, a leading innovation company for biomedical products and services has donated $25,000 to the Regents of the University of California to support the Center for Virus Research at the University of California, Irvine.

Zymo Research, a leading provider of microbiology research tools, has officially launched its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex.

Zymo Research, a leading provider in the biomedical industry, has teamed up with Burst Diagnostics, a pioneer in the rapid diagnostics industry, to launch a first-in-class diagnostic platform.

A clinical research associate is a professional who oversees clinical trials. Here are our top tips on how to become one.

Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the company hopes will save its clinical research in cancer and infectious disease.